This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.

Principal Investigator:
Elyssa Rubin, MD

Research Coordinator:
Kathryn Duvall
(714) 509-8646

Visit clinicaltrials.gov for more information about this trial.



  • Clinical Trial Info
  • IRB Number: 1412131
  • Sponsor: Children's Oncology Group
  • Protocol Number: AALL1331
  • NCT Number: NCT02101853
  • Research Type: Adolescents and Young Adults, Leukemia/Lymphoma, Recurrent/Refractory Cancer
  • Phase: III
  • Status: Active - Open to Enrollment